logo
Stock market today: Dow, S&P 500, Nasdaq futures inch up as Trump announces trade deal with Japan

Stock market today: Dow, S&P 500, Nasdaq futures inch up as Trump announces trade deal with Japan

Yahooa day ago
US stock futures edged up as President Trump announced a trade deal with Japan and Wall Street readied for Tesla (TSLA) and Alphabet (GOOGL, GOOG) earnings.
Futures attached to the Dow Jones Industrial Average (YM=F) rose 0.3%. Futures attached to the benchmark S&P 500 (ES=F) ticked up 0.2%, while the tech-heavy Nasdaq 100 (NQ=F) fluttered just above flatline.
Trump posted on Truth Social on Tuesday evening, 'We just completed a massive Deal with Japan, perhaps the largest Deal ever made." The president said that the agreement includes a 15% tariff on imported goods from Japan.
On Tuesday, stocks closed mixed, with the S&P 500 closing just above the flatline to notch a record high. Tariffs loomed large throughout the day. GM (GM) reported sinking profits due to new levies, and President Trump announced trade deals with the Philippines and Indonesia.
Read more: The latest on Trump's tariffs
Google-parent Alphabet and Tesla are set to kick off highly anticipated second-quarter results from the "Magnificent Seven" after the bell Wednesday.
Tesla CEO Elon Musk's rocky relationship with Trump is looming large over the EV maker's earnings. With its stock down nearly 18% year-to-date, investors are watching for updates on the company's core auto business and its robotaxi rollout.
With Alphabet, investors are looking for signs that AI investments are starting to pay off as the company pours billions into the technology. A federal judge's decision that could force the company to sell Google Chrome will also be in focus.
Other earnings results set to land on Wednesday include Chipotle (CMG), which is expected to report its second straight quarter of declining sales, as well as AT&T (T), IBM (IBM), and Alaska Air (ALK).
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nebraska Dems hosting Kentucky Gov. Andy Beshear, possible 2028 presidential candidate
Nebraska Dems hosting Kentucky Gov. Andy Beshear, possible 2028 presidential candidate

Yahoo

time10 minutes ago

  • Yahoo

Nebraska Dems hosting Kentucky Gov. Andy Beshear, possible 2028 presidential candidate

Kentucky Gov. Andy Beshear speaks during the Semafor World Economy Summit 2025 at Conrad Washington on April 23, 2025 in Washington, DC. () LINCOLN — Kentucky Gov. Andy Beshear is coming to Nebraska to speak to Democrats for the state party's top annual fundraising event in November. Beshear is a Democratic governor in a deeply red Republican state. He and other 2028 potential presidential hopefuls visited South Carolina in recent weeks, to test the water for their campaign messages. He was picked to lead the Democratic Governors Association into next year's midterm elections and has been touted as 'most popular Democratic governor in America.' Beshear was attorney general of Kentucky before becoming governor in 2019. His father was previously governor. National Democrats have been seeking answers as President Donald Trump made gains among working-class voters, including minority voters, last year. A trend of prominent Democratic figures making their way to the heartland has emerged, and some are crossing the Missouri River from traditionally first-in-the-nation Iowa into Nebraska. Independent U.S. Sen. Bernie Sanders launched his 'Fighting Oligarchy' nationwide tour in Omaha. Minnesota Gov. Tim Walz hosted a Democratic town hall earlier this year And Former Texas U.S. Rep. Beto O'Rourke is having a similar town hall in Omaha next month. The events with prominent Democratic figures appear aimed at energizing the Nebraska Democratic base for the midterms and come when two federal races could be competitive. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX Nebraska's 2nd Congressional District has drawn national attention as its single presidential race electoral vote has swung from Republicans to Democrats in recent years, most recently to former Vice President Kamala Harris in 2024. Nebraska could regain the national spotlight in 2026, with an open seat race in the state's 2nd District for the U.S. House and Dan Osborn's nonpartisan Senate bid against Republican U.S. Sen. Pete Ricketts. Both races could determine which party controls what parts of Congress. But Nebraska Democrats face an uphill battle in a state where Republicans outnumber Democrats about 2 to 1, Republicans have gained a legislative supermajority, and the party last held a congressional seat with former U.S. Rep. Brad Ashford in 2017. SUPPORT: YOU MAKE OUR WORK POSSIBLE

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Yahoo

time10 minutes ago

  • Yahoo

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Carlsbad, CA, July 23, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ('Palisade' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the 'Existing Warrants') to purchase up to an aggregate of 4,318,905 shares of common stock. The Existing Warrants had adjusted exercise prices of $1.40 and were issued by the Company on May 10, 2022; February 1, 2024; May 6, 2024; and December 13, 2024, with each exercise occurring at a reduced exercise price of $0.9047 per share. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this transaction. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to registration statements which were filed and declared effective by the Securities and Exchange Commission (the 'SEC'). The gross proceeds to the Company from the exercise of the Existing Warrants are expected to be approximately $3.9 million prior to deducting placement agent fees and estimated offering expenses. In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders will receive new unregistered warrants (the 'Replacement Warrants') to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the '1933 Act'). The Replacement Warrants will be exercisable, beginning on the effective date of stockholder approval, into an aggregate of up to 8,637,810 shares of common stock, at an exercise price of $0.9047 per share, and a term of exercise equal to five years from the date of shareholder approval. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The Replacement Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the 1933 Act and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Replacement Warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to Forward Looking Statements This communication contains 'forward-looking' statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: statements regarding the intended use of proceeds, the expected gross proceeds from the offering and the expected closing of the offering. These forward-looking statements are based upon the Company's current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company's forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company's clinical trials, the timing and success of preclinical studies and clinical trials conducted by the Company, the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company's product candidates in clinical trials focused on the same or different indications; and the Company's ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 24, 2025, as well as the Company's Quarterly Report on Form 10-Q, for the three-month period ended March 31, 2025, filed with the SEC on May 12, 2025. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations Contact JTC Team, LLCJenene Thomas 908-824-0775PALI@

Tesla disappoints on earnings but wins on one major front
Tesla disappoints on earnings but wins on one major front

Yahoo

time10 minutes ago

  • Yahoo

Tesla disappoints on earnings but wins on one major front

Tesla disappoints on earnings but wins on one major front originally appeared on TheStreet. Tesla didn't mention Bitcoin once in its second-quarter 2025 financial filing, even as investors and analysts scanned the company's balance sheet for any sign of movement in its crypto treasury. The silence isn't new. Tesla hasn't added or sold any Bitcoin for eight straight quarters, and the company's digital asset holdings remain unchanged at $184 million, according to the 10-Q form filed with the SEC on July 23. That's the same value it reported in the first quarter of 2024, with no impairment losses or gains noted this time either. Tesla had initially bought $1.5 billion worth of Bitcoin in early 2021. Since then, it's sold off the majority, with the last major sale happening in Q2 2022 when it offloaded roughly 75% of its BTC stash. Tesla holds 9,720 BTC as of its last disclosure. At today's Bitcoin price of $118,000, that stash is worth approximately $1.15 declines Beyond crypto, Tesla's earnings disappointed on several fronts. The company reported revenue of $22.5 billion — missing analyst estimates of $22.74 billion — and adjusted earnings per share of $0.40, below the expected $0.43. Automotive revenue fell 16% year-over-year, the second straight quarterly decline. In early July, Tesla had already reported a 14% drop in Q2 vehicle deliveries to 384,000 units. The stock is down roughly 18% this year, marking the worst performance among big tech names. By comparison, the Nasdaq Composite is up about 9% in 2025. Meanwhile, Tesla has delayed its affordable 'Model 2' EV, leaving the field open for rivals. Chinese EV makers are aggressively pushing cheaper, tech-laden vehicles that are eating into Tesla's global market share. Still holding the bag Despite the financial and political turbulence, Tesla appears to be holding firm on its crypto position—for now. But with mounting pressure from declining revenues and reputational hits, investors are watching closely for any future changes to the company's digital asset strategy. As of now, though, the Bitcoin line in Tesla's earnings reports remains quiet. No buys. No sells. Just HODLing. Tesla disappoints on earnings but wins on one major front first appeared on TheStreet on Jul 23, 2025 This story was originally reported by TheStreet on Jul 23, 2025, where it first appeared. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store